candesartan has been researched along with Anterior Choroidal Artery Infarction in 8 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan treatment alleviated matrisome protein accumulation and normalized the vascular distensibility and cerebral blood flow." | 1.62 | Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model. ( Ando, S; Fujita, N; Fukunaga, M; Hasegawa, M; Hatano, Y; Hirokawa, S; Igarashi, H; Ihara, M; Kakita, A; Kametani, F; Kanazawa, M; Kato, T; Kawashima, Y; Kawata, H; Koyama, A; Manabe, RI; Matsumoto, M; Murayama, S; Nishizawa, M; Nozaki, H; Onodera, O; Saito, R; Saito, S; Sato, T; Sekine, Y; Sugai, A; Sugie, A; Toyoshima, Y; Tsuji, S; Uemura, M, 2021) |
| "A 31-year-old woman developed bilateral posterior ischemic optic neuropathy and infarctions of the cerebral arterial border zones and spinal cord after correction of malignant hypertension." | 1.35 | Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension. ( An, SJ; Choi, JH; Choi, KD; Kim, HJ; Kim, JS; Lee, JE, 2008) |
| "However, the endothelin-1 (ET-1)-induced middle cerebral artery occlusion (MCAO) model of cerebral ischaemia is thought to more closely mimic the temporal events of an embolic stroke." | 1.35 | Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. ( Katovich, MJ; Mecca, AP; O'Connor, TE; Sumners, C, 2009) |
| "pretreatment with candesartan, 0." | 1.32 | Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. ( Blume, A; Culman, J; Gohlke, P; Groth, W; Unger, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, T | 1 |
| Manabe, RI | 1 |
| Igarashi, H | 1 |
| Kametani, F | 1 |
| Hirokawa, S | 1 |
| Sekine, Y | 1 |
| Fujita, N | 1 |
| Saito, S | 1 |
| Kawashima, Y | 1 |
| Hatano, Y | 1 |
| Ando, S | 1 |
| Nozaki, H | 1 |
| Sugai, A | 1 |
| Uemura, M | 1 |
| Fukunaga, M | 1 |
| Sato, T | 2 |
| Koyama, A | 1 |
| Saito, R | 1 |
| Sugie, A | 1 |
| Toyoshima, Y | 1 |
| Kawata, H | 1 |
| Murayama, S | 1 |
| Matsumoto, M | 1 |
| Kakita, A | 1 |
| Hasegawa, M | 1 |
| Ihara, M | 1 |
| Kanazawa, M | 1 |
| Nishizawa, M | 1 |
| Tsuji, S | 1 |
| Onodera, O | 1 |
| Choi, JH | 1 |
| Choi, KD | 1 |
| Kim, JS | 1 |
| Kim, HJ | 1 |
| Lee, JE | 1 |
| An, SJ | 1 |
| Mecca, AP | 1 |
| O'Connor, TE | 1 |
| Katovich, MJ | 1 |
| Sumners, C | 1 |
| Yamakawa, H | 1 |
| Jezova, M | 1 |
| Ando, H | 1 |
| Saavedra, JM | 1 |
| Groth, W | 1 |
| Blume, A | 1 |
| Gohlke, P | 1 |
| Unger, T | 1 |
| Culman, J | 1 |
| Fukui, T | 1 |
| Rahman, M | 1 |
| Hayashi, K | 1 |
| Takeda, K | 1 |
| Higaki, J | 1 |
| Fukushima, M | 1 |
| Sakamoto, J | 1 |
| Morita, S | 1 |
| Ogihara, T | 1 |
| Fukiyama, K | 1 |
| Fujishima, M | 1 |
| Saruta, T | 1 |
| Schrader, J | 1 |
| Diener, HC | 1 |
| Lüders, S | 1 |
| Engelhorn, T | 1 |
| Doerfler, A | 1 |
| Heusch, G | 1 |
| Schulz, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients[NCT00125463] | Phase 3 | 3,200 participants | Interventional | 2001-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cerebral Hemorrhage; Cerebral Infarctio | 2003 |
7 other studies available for candesartan and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model.
Topics: ADAMTS Proteins; Alopecia; Animals; Benzimidazoles; Biphenyl Compounds; Cerebral Infarction; Cerebro | 2021 |
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Brain; Brain Stem Infarctions; C | 2008 |
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia | 2009 |
Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterial Occlusive Diseases; Ben | 2003 |
Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2003 |
[Treating high blood pressure in acute stroke].
Topics: Acute Disease; Adrenergic alpha-Agonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2004 |
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebra | 2006 |